In 1970 the glucagon precursor, proglucagon, was identified
Half the participants received a weekly injection of semaglutide, first at the very low dose of 0.25 mg, then after 4 weeks at 0.5 mg, and finally at 1 mg in the 9th and final week of the trial (the typical maximum dose for weight loss is 2.4mg/week)
The trial was conducted at three centers in Pakistan
The circulating concentrations of GLP-1 RA activity are much higher than physiological levels of GLP-1 activity (22)
No reader of this post should act or refrain from acting on the basis of any information included in, or accessible through, this post without seeking the appropriate medical advice on the particular facts and circumstances at issue from a licensed medical professional in the recipients state, country or other appropriate licensing jurisdiction.
Additionally, weight loss with semaglutide was associated with improvements in cardiovascular risk factors and physical fitness